Osteogenesis imperfecta (OI) - Pipeline Insight, 2024

This Osteogenesis imperfecta (OI) - Pipeline Insight, 2024,” report provides comprehensive insights about 14+ companies and 18+ pipeline drugs in Osteogenesis imperfecta (OI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Osteogenesis imperfecta (OI) Understanding

Osteogenesis imperfecta (OI): Overview

Osteogenesis imperfecta (OI), also known as Brittle Bone Disease, is a clinically and genetically heterogeneous group of heritable disorders of connective tissue. The hallmark feature of OI is bone fragility, with a tendency to fracture from minimal trauma or from the work of bearing weight against gravity. In the more severe forms of the disorder, the bones are deformed as well as fragile. Most individuals with OI have significant physical disabilities. Affected persons also exhibit an array of associated features, including short stature, macrocephaly, blue sclerae, dentinogenesis imperfecta, hearing loss and neurological and pulmonary complications. Autosomal dominant OI types occur at comparable frequency in different genders, races, and ethnic groups.

Osteogenesis imperfecta (OI) - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteogenesis imperfecta (OI) pipeline landscape is provided which includes the disease overview and Osteogenesis imperfecta (OI) treatment guidelines. The assessment part of the report embraces, in depth Osteogenesis imperfecta (OI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteogenesis imperfecta (OI) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteogenesis imperfecta (OI) R&D. The therapies under development are focused on novel approaches to treat/improve Osteogenesis imperfecta (OI).

This segment of the Osteogenesis imperfecta (OI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Osteogenesis imperfecta (OI) Drugs
Setrusumab: Mereo Bio Pharma Setrusumab is a fully human monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway that inhibits the activity of bone-forming cells. The goal of blocking inhibitory effects of sclerostin is to increase new bone formation, bone mineral density, and bone strength. Sclerostin inhibition also reduces excessive bone resorption, further enhancing its impact on bone density. In various mouse models of OI, the use of anti-sclerostin antibodies was shown to stimulate bone formation, improve bone mass and density, and reduce bone fragility as reflected in increased long bone strength and reduced the number offractures.

Osteogenesis imperfecta (OI): Therapeutic Assessment

This segment of the report provides insights about the Osteogenesis imperfecta (OI) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Osteogenesis imperfecta (OI)

There are approx. 14+ key companies which are developing the therapies for Osteogenesis imperfecta (OI). The companies which have their Osteogenesis imperfecta (OI) drug candidates in the most advanced stage, i.e. Phase III include Mereo BioPharma.

Phases

This report covers around 18+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Osteogenesis imperfecta (OI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Osteogenesis imperfecta (OI): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Osteogenesis imperfecta (OI) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteogenesis imperfecta (OI) drugs.

Osteogenesis imperfecta (OI) Report Insights

• Osteogenesis imperfecta (OI) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Osteogenesis imperfecta (OI) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Osteogenesis imperfecta (OI) drugs?
• How many Osteogenesis imperfecta (OI) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteogenesis imperfecta (OI)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteogenesis imperfecta (OI) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Osteogenesis imperfecta (OI) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanofi
• Novosteo
• Amgen
• Mereo BioPharma
• Amgen/UCB
• Adge Pharmaceuticals
• Keros Therapeutics

Key Products

• SAR 439459
• NOV 004
• Denosumab
• Setrusumab
• Romosozumab
• Elocalcitol
• KER 012

This product will be delivered within 2 business days.